tbuckley/cabot-search huggingface dataset:
Abstract P333: What is the Association between Severe Mental Illness and Hypertension Recognition, Treatment, and Control?
Authors: Jay R Desai, Gabriela Vazquez-Benitez, David Magid, Julie Schmittdiel, Rebecca Rossom, Greg Simon, Patrick O'Connor
Journal: Circulation (2013)

Background: Severe mental illness (SMI; bipolar disorder and schizophrenia) are associated with a 25-year decrease in lifespan, much of which is due to cardiovascular disease. SMI may delay the identification, treatment or control of hypertension (HT), in part due to competing demands for provider attention and the impact of SMI on patient adherence to HT treatment. Objective: To test whether incident HT patients with SMI had worse HT recognition, treatment initiation and control than patients without SMI. Methods: Insured patients 19 years of age and older with HT onset were identified from three large health systems from January 1, 2003 to December 31, 2008 based on combinations of elevated blood pressure readings (≥ 140/90 mmHg or ≥ 130/80 mmHg if diabetes or chronic kidney disease), HT diagnosis codes, and anti-HT prescription fills. SMI diagnoses were based on at least one inpatient or outpatient diagnosis code for bipolar disorder or schizophrenia. Comparison populations were 10:1 age- and gender-ma...
Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens.
Authors: E A Wiebke, S A Rosenberg, M T Lotze
Journal: Journal of Clinical Oncology (1988)

We prospectively evaluated responses to recall antigen in ten cancer patients undergoing immunotherapy and correlated these responses with in vitro proliferation data. Before therapy, eight of ten patients responded normally to at least two of seven antigens of a multitest system (greater than or equal to 2 mm induration at 48 hours), with a mean induration score of 17.9 +/- 4.4 mm and 2.7 +/- 0.5 positive responses per patient. This decreased to 5.9 +/- 2.7 mm (P = .01) and 1.2 +/- 0.5 responses (P = .03) after a week of interleukin-2 (IL-2) therapy, and further to 0.7 +/- 0.7 mm and 0.1 +/- 0.1 positive responses during a second week of therapy consisting of IL-2 plus activated autologous lymphocytes (P less than .01). The in vitro proliferation indices for lymphocytes obtained before skin test application were significantly less after IL-2 compared with pretreatment for concanavalin A ([con-A] Miles Laboratory, Elkhart, IN) stimulation (3.3 +/- 0.7 to 1.3 +/- 0.1; P = .03) and in mixed lymphocyte culture (MLC) (41.5 +/- 8.5 to 16.8 +/- 3.8; P = .02), and during the second week of therapy for in vitro IL-2 stimulation (83.3 +/- 16.8 to 42.9 +/- 12.0; P less than .01). When skin responses were directly compared with in vitro proliferation data, a significant correlation was observed for tetanus (r = .75; P less than .01), streptococcal antigen (r = .83; P less than .01), tuberculin (r = .83; P less than .01), and candida (r = .78; P less than .01). Thus, significant decreases in skin test responses and in vitro proliferation were demonstrated after therapy compared with pretreatment. Flow cytometry revealed marked increases in T-lymphocyte numbers after IL-2 alone (973 +/- 252 to 3,436 +/- 754 cells/mL; P less than .01) and IL-2 receptor-bearing cells (105 +/- 28 to 983 +/- 215; P less than .01), but not in numbers of B-lymphocytes or monocytes. Induced anergy to skin test antigens was seen during a period of relative and absolute T-lymphocyte expansion. We conclude that immunotherapy with high-dose IL-2 with or without activated lymphocytes results in a decreased response to recall antigens during a period in which lymphoid cells with nominal activation markers (Tac, DR) increase.
Abstract P373: Changes in Adipokines with Weight Loss and Regain in a 24-Month Behavioral Weight Loss Study: The SMART Trial
Authors: Lora E Burke, Erica Ambeba, Lei Ye, Mindi Styn, Sushama Acharya, Susan Sereika, Lewis Kuller
Journal: Circulation (2012)

Background: Weight regain commonly occurs in many adults who intentionally lose weight. Failure to maintain weight loss can lead to an increased risk for chronic diseases, such as type 2 diabetes and atherosclerosis. A potential mechanism behind the increased risk includes the increased secretion of pro-inflammatory adipokines (TNF-α and IL-6) and the decreased secretion of anti-inflammatory adipokines (adiponectin and IL-10). Objectives: We conducted an ancillary study to a 24-month behavioral weight loss trial. The purpose of the study was to examine the association between weight loss and regain and changes in body fat from baseline to 24 months and changes in TNF-α, IL-6, IL-10, and adiponectin. Methods: The analysis included a subsample of participants (n=67) from the SMART Trial who lost and regained at least 10 lbs during the 24-month trial. All participants received standard behavioral treatment for weight loss in group sessions during the first 18 months beginning with weekly sessions, which decreased in frequency over time. Linear mixed modeling was used to examine the association of percent changes in weight and body fat with percent changes in adipokines. Results: The sample was 81% female and 87% White with a mean (±SD) age of 48.4±7.34 years. At entry into study the mean weight was 96.4±15.6 kg and mean BMI was 34.5±4.35 kg/m 2 . Percent body fat was on average 42.1±6.13%. Mean weight change from baseline to six months was -10.7±5.19% and from baseline to 24 months was -3.34±6.66% while mean change in percent body fat was -8.07±11.6% from baseline to six months and -3.03±9.57% from baseline to 24 months. Weight loss over time was significantly associated with an increase in adiponectin [b(se)=-1.7(0.34), p&lt;.0001] and a decrease in IL-6 [b(se)=1.26(0.49), p=0.01]. A similar pattern of associations was observed for reduction in body fat over time with an increase for adiponectin [b(se)=-0.76(0.19), p&lt;.0001] and a decrease for IL-6 [b(se)=0.68(0.25), p=.006]. There were no significant associations found for either weight loss or change in percent body fat with change in IL-10 [weight: b(se)=0.51(0.54), p=.35; body fat: b(se)=0.43(0.28), p=.12] and TNF-alpha [weight: b(se)=0.35(0.44), p=.43; body fat: b(se)=0.19(0.24), p=.43] over 24-months. Conclusion: Weight loss and reduction in body fat were significantly associated with improvements in two of the adipokines. However, by 24 months, when weight regain occurred, those changes were attenuated. Implementing strategies that support healthy behaviors and sustained weight loss can help prevent a state of chronic systemic inflammation and prevent adverse health outcomes.
Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent Glioblastoma Multiforme: Interim results
Authors: M. A. Vogelbaum, D. Peereboom, G. Stevens, G. Barnett, C. Brewer
Journal: Journal of Clinical Oncology (2004)

1558 Background: Erlotinib (Tarceva, OSI-774) is an orally available small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. We have initiated the first phase II trial of erlotinib in single agent therapy of recurrent glioblastoma multiforme (GBM). Methods: Patients with documented recurrent or progressive GBM who have received previous radiation therapy and cytotoxic chemotherapy were eligible for enrollment. No enzyme-inducing anti-epileptic agents were allowed. Patients were treated with 150 mg of erlotinib per day until tumor progression or study withdrawal. Tumor response was determined by MRI. Analysis for EGFR amplification was performed. Results: Interim analysis has been performed on a total of 16 of 31 planned patients as of December, 2003. Of these, 4 patients have shown partial responses, 1 showed a partial response of his original tumor but then developed a separate unresponsive focus and 4 have had disease stabilization for greater than 3 months. Seven patients have had tumor progression within 3 months of starting erlotinib. Although a response has been seen in 50% of patients (4 PR + 4 SD), the responses have not been durable; the median time to progression of responders has been 145 days after the start of therapy. Eleven patients have died since the start of the study. The pattern of subsequent treatment failure in responders has suggested a diffuse spread of tumor (e.g. gliomatosis cerebri or leptomeningeal spread). One patient had a tumor-associated cyst in which the steady state OSI-774 level was determined and found to be approximately 40% of that observed in plasma. Approximately one-half of the tumors have had EGFR amplification, but EGFR amplification has not ensured a response to erlotinib and responses have been observed in the absence of amplification. Conclusions: Although these results are preliminary in nature, we are encouraged by the response rate observed to date. The apparent lack of durability of response and the pattern of post-response failure may be due, in part, to reduced drug penetration into the brain, an inadequate dose and/or tumor heterogeneity. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech
A novel erythropoiesis-stimulating agent (AMG114) with 131-hour half-life effectively treats chemotherapy-induced anemia when administered as 200 mcg every 3 weeks
Authors: A. C. Österborg, R. De Boer, M. Clemens, G. Renczes, D. Kotasek, J. Prausova, N. Marschner, M. Hedenus, L. Hendricks, R. Amado
Journal: Journal of Clinical Oncology (2006)

8626 Background: In treating chemotherapy-induced anemia (CIA), erythropoiesis-stimulating agents (ESAs) that can be administered every 3 wks (Q3W), a common chemotherapy schedule, are convenient for patients (pts) and minimize resource utilization. AMG114 is a hyperglycosylated analog of recombinant human erythropoietin, with 4 additional N-linked carbohydrates and 10-amino acid difference from human erythropoietin. In vitro and in vivo animal data for AMG114 predict increased biological activity and prolonged half-life compared with commercially available ESAs. Methods: This multicenter, randomized, double-blind, placebo-controlled, dose-finding, phase 1 study evaluated safety, pharmacokinetics (PK), and efficacy of AMG114 administered subcutaneously Q3W in anemic pts (hemoglobin [Hb] ≥ 8.5 and ≤ 10.5 g/dL) with nonmyeloid malignancies receiving nonplatinum chemotherapy. Patients received AMG114 or placebo for 6 wks (ie, 3 administrations), followed by 3 wks of observation. Efficacy was assessed by Hb change from baseline. Results: Three doses were tested in sequential dose escalation cohorts (including pts receiving placebo): 15 (n=10), 50 (n=18), and 200 (n=20) mcg. Tumor types were: breast (33.3%), non-Hodgkin’s lymphoma, pancreatic, and colorectal (12.5% each). Consistent with animal PK models, the 200-mcg cohort had adequate levels of AMG114 for evaluation of prespecified endpoints (Table). The safety profile of AMG114 was similar to placebo and expected for this population. Antibodies to AMG114 were not detected. Conclusions: AMG114, a novel ESA with an extended 131-hour half-life, appears to be safe and effective at stimulating erythropoiesis and raising Hb levels using 200 mcg Q3W. Although the need for new longer-acting ESAs in the CIA setting may be limited as it is possible to synchronize anemia therapy with most chemotherapy schedules using currently available ESAs, AMG114 may hold promise in other settings. [Table: see text] [Table: see text]
P0910 : No evidence of pharmacokinetic drug–drug interaction in healthy subjects between coadministered grazoprevir (MK-5172)/elbasvir (MK-8742) and sofosbuvir
Authors: W.L. Marshall, W.W. Yeh, D. Stypinski, P. Auger, C. Bethel-Brown, L. Caro, P. Jumes, X. Huang, Z. Guo, M. Martinho, H.-P. Feng, D. Armas, J. Brejda, M. Iwamoto, J.R. Butterton
Journal: Journal of Hepatology (2015)
Bacterial neonatal sepsis and antibiotic resistance in low-income countries
Authors: Bich-Tram Huynh, Michael Padget, Benoit Garin, Elisabeth Delarocque-Astagneau, Didier Guillemot, Laurence Borand, Thida Chon, Agathe de Lauzanne, Sophie Goyet, Sopheak Hem, Alexandra Kerleguer, Siyin Lach, Veronique Ngo, Arnaud Tarantola, Sok Touch, Jean-Marc Collard, Perlinot Herindrainy, Patrice Piola, Bodonirina Tanjona Raheliarivao, Frédérique Randrianirina, Awa Ndir, Vincent Richard, Abdoulaye Seck, Raymond Bercion, Amy Gassama Sow, Jean Baptiste Diouf, Pape Samba Dieye, Balla Sy, Bouya Ndao, Maud Seguy, Elsa Kermorvant-Duchemin, Laurence Watier
Journal: The Lancet (2016)
Fcgamma RIIa polymorphism in systemic lupus erythematosus
Authors: L J C Smyth, N Snowden, D Carthy, C Papasteriades, A Hajeer, W E R Ollier
Journal: Annals of the Rheumatic Diseases (1997)

Polymorphism of the phagocyte IgG receptor Fc gamma RIIa may modulate immune complex mediated inflammation, particularly when immune complexes contain IgG2. Previous studies suggest that this polymorphism may be an important risk factor for lupus nephritis. Fc gamma RIIa is biallelic, the alleles R and H each having a gene frequency of about 50%. Nephritis has been associated with an increased frequency of the R allele. The frequency of common Fc gamma RIIa alleles was examined in white subjects from the United Kingdom and Greek subjects with systemic lupus erythematosus (SLE) and healthy controls.Fc gamma RIIa genotyping was performed using a single step polymerase chain reaction technique, which differentiates the two major alleles, R and H. Two study populations were examined: (a) white subjects from the United Kingdom: 66 controls and 81 with SLE (19 of whom had renal disease) and (b) Greek: 52 controls and 42 with SLE (19 with renal disease).No significant relation was observed between Fc gamma RIIa genotype and susceptibility to SLE or SLE nephritis.The Fc gamma RIIa R allele does not seem to be associated with SLE (with or without renal disease) in our United Kingdom white or Greek populations.
Attitudes of consultant physicians to Calman proposals
Authors: D. London
Journal: BMJ (1995)

initial marking, it is impossible to sit beside one's coexaminer for 30 minutes without forming a (usually accurate) impression of what the co- examiner's mark is likely to be.All of these factors would tend to increase the interexaminer agreement but not necessarily increase the reliability of the vivas.A more thorough analysis would enable us to judge whether the commonly held view that vivas are inherently unreliable can now be revised.
PANVAC vaccine alone or with docetaxel for patients with metastatic breast cancer
Authors: M. Mohebtash, R. A. Madan, J. L. Gulley, J. Jones, M. Pazdur, M. Rauckhorst, J. Schlom, P. M. Arlen
Journal: Journal of Clinical Oncology (2008)

3035 Background: PANVAC (V) is a recombinant pox viral vaccine that targets the TAAs (tumor associated antigens) MUC1 and CEA. V also contains three T-cell co-stimulatory molecules (B7.1, LFA-3, ICAM-1). Clinical studies with a similar vaccine have shown docetaxel (D) does not diminish specific T-cell responses to the TAAs delivered in the pox viral vaccines. We are evaluating the use of V in 2 ongoing trials in patients (pts) with metastatic breast cancer. One study utilizes V alone, another applies V+D. Methods: These two phase II trials’ primary endpoints are progression-free survival (PFS). V is administered by monthly subcutaneous injections and is accompanied by 4 days of low dose GM-CSF. The V + D protocol uses the same V regimen plus D at 35 mg/m2 dose given on days 2, 9, and 16 of each 28 day cycle. Results: 15 pts have been accrued with median age of 61 (40–75) years. Eight pts are ER/PR positive. Pts had a median of 3 (1–6) previous chemotherapy regimens and a median of 105 (12–730) days since their last chemotherapy. V is well tolerated with few grade 3 and no grade 4 adverse events. Most of the grade 1–2 toxicities were self-limited site reactions and flu-like symptoms. Three of 11 pts on V alone study have shown measurable clinical benefits. Two were on study for 6 months, of whom one had a significant improvement in pain with reduction in vertebral lesions on MRI; another had a sustained >20% decrease in bulky liver metastases. A third pt on V alone was on study for 10 months with a partial response (PR) by RECIST criteria. Of 4 pts who received V+D, 3 had measurable disease and 1 achieved PR by RECIST, another had a 50% reduction in the diameter of a chest wall lesion. A third pt with bone only disease was on study for 12 months with improvement on her bone scan. Conclusions: Both V alone and V+D have been shown to be safe in pts with metastatic breast cancer. There is preliminary evidence that there may be some clinical benefit from V alone as well as V+D. Confirmation of these results and PFS determination requires additional pt enrollment and follow up in both studies. Furthermore, immunologic studies including functional analysis of CD4 and CD8 T-cells and enumeration of regulatory T-cells will be performed to help elucidate the immune responses V may elicit. No significant financial relationships to disclose.
Abstract 12097: Renal Impairment in Acute Heart Failure: Insights From a Managed Care Database
Authors: Jason Swindle, Wing Chan, Katherine Waltman Johnson, Laura Becker, Cori Blauer-Peterson, Aylin Riedel
Journal: Circulation (2013)

Background: Multiple epidemiological studies have suggested that comorbid renal impairment is associated with an elevated risk of poor outcomes in heart failure (HF). This study examined short-term...
Preparation of Cell-Free Feline Oncornavirus-Associated Cell Membrane Antigen2
Authors: Linda H. Wolff, Richard G. Olsen, Edward A. Hoover, David S. Yohn, Joseph P. Schaller
Journal: JNCI Journal of the National Cancer Institute (1977)

Cell-free feline oncornavirus-associated cell membrane antigen (FOCMA) was prepared from a feline Iymphoblastoid cell line of tumor origin (FL-74). Membrane fractions, separated on sucrose density gradients, and papain-solubilized products were found to contain FOCMA as determined by their capacity to inhibit reference cytotoxic cat antisera.
Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia: A phase II study from the North Central Cancer Treatment Group
Authors: A. Jatoi, B. Murphy, N. Foster, D. Nikcevich, S. Alberts, J. Kugler, T. Fitch, R. F. Luyun
Journal: Journal of Clinical Oncology (2005)

4059 Purpose: The synergistic combination of oxaliplatin and capecitabine has demonstrated activity against various gastrointestinal malignancies. To our knowledge, however, this combination has not been reported in the first-line setting in patients with metastastic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. Patients and Methods: 44 virtually chemotherapy-naïve patients (4 had received radiosensitizing chemotherapy) with histologic or cytologic proof of the above disease, an ECOG performance score of 0, 1, or 2 (45%, 53%, and 2%, respectively), and a median age of 62 years (range: 32–80) were enrolled. All had adequate organ function. Initially, patients were prescribed oxaliplatin 130 mg/m2 intravenously on day 1 and capecitabine 1000 mg/m2 orally twice a day, days 1–14 of a 21-day cycle. Three treatment-related deaths in the first 24 patients prompted a reduction in capecitabine to 850 mg/m2 orally twice a day, days 1–14 for the remainder of the cohort. Results: The tumor response rate was 34% (95% confidence interval (CI): 22%, 49%). All were partial; 7/24 occurred before the capecitabine dose reduction, and 8/20 after. Median time to tumor progression was 3.8 months (95% CI: 3.0, 4.6 months), and median survival 6.4 months (95% CI: 4.1, 10.9 months). To date, there have been 30 deaths. Three were treatment-related (1 infection, 2 myocardial infarction), all of which occurred prior to the capecitabine dose reduction. Notable grade 4 adverse events from the entire cohort included diarrhea (2 patients), vomiting (3), dyspnea (1), thrombosis (2), anorexia (2). Grade 3 events included nausea (12 patients), diarrhea (12), fatigue (10), abdominal pain (7), vomiting (6), dyspnea (6), dehydration (5), hypokalemia (5), infection (3). Conclusions: This combination of oxaliplatin and capecitabine demonstrates activity in metastastic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. The lower dose of capecitabine (850 mg/m2 orally twice a day, days 1–14) yielded an acceptable toxicity profile. Further study of this regimen appears warranted. No significant financial relationships to disclose.
Abstract P129: Mid-Life Blood Lipid Levels, Blood Pressure and Smoking in Men: Relation With 5-yr CHD Incidence Compared to Associations With Multi-Morbidity Among Survivors at Late Life
Authors: Uri Goldbourt, David Tanne
Journal: Circulation (2015)

Background:  Interest in understanding CHD risk factors observable at earlier age and associated with late-life morbidity has been increasing as case fatality declined and life expectancy rose. The Charlson Comorbidity Index (CCI) developed in 1987 was designed to develop a prospectively applicable method for classifying comorbid conditions  Patients, methods . An extensive examination of 10,000 men, civil servants, aged 40-65 yr, took place in 1963. They were reexamined in 1965 and 1968 and the 5-yr incidence of CHD was assessed. Over three decades later, CCI was available for 75% of the survivors, who were insured with a large national HMO (“Clalit“).  We grouped the CCI categories of 1-17 into grouped scores (CCS) in five groups: CCI=7. Odds ratios and hazard ratios (HR) for these endpoints in relation to total HDL and non-HDL cholesterol and risk factor levels were estimated applying multiple logistic regression.   Results:  The 5-yr incidence (1963-68) of CHD was 27, 31, 48 and 68 per 1000 in the first to fourth quartile of total serum cholesterol; and 30, 33, 41 and 64/1000 in corresponding percentiles of non-HDL cholesterol. Multivariate-adjusted hazard ratios for the latter were 1, 1.12, 1.32 and 2.23 (p for trend   Comment:  Despite the remoteness of multi-morbid classification in 2002 from baseline levels in the mid 19609s, mid-life lipid components which had remarkably predicted the incidence of CHD were also related moderately to late-life multi-morbidity, among survivors aged>79 years, in addition to cigarette smoking and blood pressure visit- to-visit increment. The serum lipid levels also explained away the increased late life survivors9 morbidity among mid-life overweight and obese men.